Newton H B, Page M A, Junck L, Greenberg H S
Department of Neurology, University of Michigan Hospitals, Ann Arbor 48109.
J Neurooncol. 1989 May;7(1):39-45. doi: 10.1007/BF00149377.
Cisplatin (DDP) is a chemotherapeutic agent that has shown efficacy against primary CNS malignancies. Intra-arterial (IA) administration of DDP to patients with brain tumors should produce higher peak levels of drug than intravenous (IV) administration of an identical dose and reduce systemic toxicity. Twelve patients with malignant glioma were entered into the study. All had failed irradiation, 11 had failed IA BCNU. Each patient received IA DDP, 58-100 mg/m2, into the internal carotid artery at four to six week intervals. One of 12 patients had a partial response of 6 months. The remaining 11 patients had progressive disease or severe complications. Toxicity included seizures in four patients, weakness and/or aphasia in four patients, coma in two patients, and visual deterioration in two patients. IA DDP has very limited efficacy in patients with malignant gliomas after failure of nitrosoureas and is associated with an unacceptable level of toxicity. IA DDP may be more effective when used as initial chemotherapy of malignant gliomas.
顺铂（DDP）是一种已显示出对原发性中枢神经系统恶性肿瘤有效的化疗药物。对脑肿瘤患者进行顺铂动脉内（IA）给药，与静脉内（IV）给予相同剂量相比，应能产生更高的药物峰值水平，并降低全身毒性。12例恶性胶质瘤患者进入该研究。所有患者放疗均失败，11例动脉内卡氮芥治疗失败。每位患者每隔四至六周经颈内动脉接受58 - 100 mg/m²的动脉内顺铂治疗。12例患者中有1例出现了6个月的部分缓解。其余11例患者病情进展或出现严重并发症。毒性反应包括4例患者发生癫痫，4例患者出现虚弱和/或失语，2例患者昏迷，2例患者视力减退。在亚硝基脲类药物治疗失败后的恶性胶质瘤患者中，动脉内顺铂的疗效非常有限，且伴有不可接受的毒性水平。当作为恶性胶质瘤的初始化疗时，动脉内顺铂可能更有效。
